218 related articles for article (PubMed ID: 32812415)
1. Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma.
Luo Y; Gui R
Turk J Haematol; 2020 Nov; 37(4):248-262. PubMed ID: 32812415
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma.
Luo Y; Ma J; Liu F; Guo J; Gui R
Head Neck; 2020 Dec; 42(12):3702-3711. PubMed ID: 32945062
[TBL] [Abstract][Full Text] [Related]
3. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
4. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
5. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of circulating exosomal miRNAs in multiple myeloma.
Manier S; Liu CJ; Avet-Loiseau H; Park J; Shi J; Campigotto F; Salem KZ; Huynh D; Glavey SV; Rivotto B; Sacco A; Roccaro AM; Bouyssou J; Minvielle S; Moreau P; Facon T; Leleu X; Weller E; Trippa L; Ghobrial IM
Blood; 2017 Apr; 129(17):2429-2436. PubMed ID: 28213378
[TBL] [Abstract][Full Text] [Related]
7. Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer.
Ding XZ; Zhang SQ; Deng XL; Qiang JH
Technol Cancer Res Treat; 2021; 20():1533033821990060. PubMed ID: 33550924
[TBL] [Abstract][Full Text] [Related]
8. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
9. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma.
Lee YR; Kim G; Tak WY; Jang SY; Kweon YO; Park JG; Lee HW; Han YS; Chun JM; Park SY; Hur K
Int J Cancer; 2019 Mar; 144(6):1444-1452. PubMed ID: 30338850
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
11. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer.
Liu T; Zhang X; Gao S; Jing F; Yang Y; Du L; Zheng G; Li P; Li C; Wang C
Oncotarget; 2016 Dec; 7(51):85551-85563. PubMed ID: 27888803
[TBL] [Abstract][Full Text] [Related]
12. Underlying metastasis mechanism and clinical application of exosomal circular RNA in tumors (Review).
Wei X; Shi Y; Dai Z; Wang P; Meng X; Yin B
Int J Oncol; 2021 Mar; 58(3):289-297. PubMed ID: 33650643
[TBL] [Abstract][Full Text] [Related]
13. Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related peripheral neuropathy.
Zhang Y; Pisano M; Li N; Tan G; Sun F; Cheng Y; Zhang Y; Cui X
Cell Signal; 2021 Feb; 78():109872. PubMed ID: 33290841
[TBL] [Abstract][Full Text] [Related]
14. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
15. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
16. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer.
Zhao R; Zhang Y; Zhang X; Yang Y; Zheng X; Li X; Liu Y; Zhang Y
Mol Cancer; 2018 Feb; 17(1):68. PubMed ID: 29486794
[TBL] [Abstract][Full Text] [Related]
17. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
[TBL] [Abstract][Full Text] [Related]
18. High expression of circulating exosomal circAKT3 is associated with higher recurrence in HCC patients undergoing surgical treatment.
Luo Y; Liu F; Gui R
Surg Oncol; 2020 Jun; 33():276-281. PubMed ID: 32561093
[TBL] [Abstract][Full Text] [Related]
19. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Zhan Y; Du L; Wang L; Jiang X; Zhang S; Li J; Yan K; Duan W; Zhao Y; Wang L; Wang Y; Wang C
Mol Cancer; 2018 Sep; 17(1):142. PubMed ID: 30268126
[TBL] [Abstract][Full Text] [Related]
20. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
